

Comparison of Major COVID-19 Early Treatment Pharmaceuticals: Color Codes

COLOR CODE		RED	BLACK	GREEN
Translation		Worst	Average	Best
Effectiveness	Total Number of all COVID-19 Studies	1 to 9	10 to 20	20+
	Total Number of all Study Participants	1 to 999	1000 to 10,000	10,000+
	Number of Early Treatment Studies (ET)	1 to 5	6 to 10	10+
	Number of ET Study Participants	1 to 999	1000 to 10,000	10,000+
	Overall ET Effectiveness	1% to 39%	40% to 59%	60% +
	Number of ET Hospital/Death Studies (ET1)	1 to 5	6 to 10	10+
	Number of ET1 Study Participants	1 to 999	1000 to 5,000	5,000+
	Number of Larger ET1 Studies (ET2)	1 to 5	6 to 10	10+
	Number of ET2 Study Participants	1 to 999	1000 to 10,000	10,000+
	ET2 Hospital & Death Reduction	1% to 39%	40% to 59%	60% +
Safety	Number of Human Doses	< 1 Million	1 M to 1 Billion	1 Billion+
	Any Long Term Safety Data	No	NA	Yes
	Safe for Persons with Common Diseases	Unknown	NA	Yes
	Potential Side Effects	Serious	Moderate	Mild
	How is it administered	Injection or Infusion	NA	Pill
Cost	Total Treatment Drug Cost	> \$100	\$10 to \$100	< \$10
	How Drug is Purchased	Requires Physician	NA	OTC

For questions, comments or possible errors (please provide the evidence), email physicist

[John Droz, jr.](mailto:John.Droz.jr@medrxiv.org)

Revision: 8-29-22